Nephros, Inc. (NEPH)

Nephros, Inc.'s stock price has experienced volatility, gaining 70.9% over the past 12 months but declining approximately 30% over the last six months. Key events include Q1 2026 financial results showing revenue growth but declining net income and adjusted EBITDA due to lower gross margins. The company expanded its water safety capabilities with ASSE 12080 Legionella Water Safety and Management Specialist Certification. Additionally, SEC filings indicated that the CEO and CFO exercised stock options.

While no explicit information on demand seasonality for Nephros, Inc.'s products and services was found, the nature of its business suggests a relatively stable demand with some potential fluctuations. The company's "programmatic business" is a core driver of predictable revenue. The company also provides "emergency solutions for water management," and its Q1 2026 earnings report indicated that emergency response revenue declined compared to an elevated prior-year quarter, suggesting that this segment can experience event-driven spikes in demand. The expansion into broader commercial applications like ice machines, drinking fountains, and hospitality also aims to diversify its revenue base and build scale.

Nephros, Inc. is a healthcare company specializing in water purification and filtration solutions for medical and commercial markets. It develops and sells water filtration solutions, including ultrafiltration products for dialysis centers and hospitals, and water filters for commercial applications. The company also focuses on pathogen detection products and is developing a second-generation hemodiafiltration system.

Nephros, Inc. primarily operates in the United States and is expanding its geographic reach, focusing on markets such as Greater New York and Puerto Rico.

Nephros, Inc. maintains a reputation for providing innovative water filtration technology and water-quality education. The company emphasizes its commitment to improving the human relationship with water through accessible technology and its expertise in rigorous FDA Class II medical filters. Recent positive sentiment has been observed in relation to the company's strategic expansion into new commercial applications and its customer-centered initiatives. The expansion of its water safety capabilities with ASSE 12080 certification further strengthens its reputation as a trusted resource in water filtration.

Nephros, Inc.'s ownership is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 3.54% to 5.48% of the company's stock, while insiders hold around 4.87%. Public companies and individual investors account for a significant portion, ranging from 1.94% to 89.65%. Major institutional owners include Wexford Capital Lp, Topline Capital Management, LLC, Vanguard Group Inc, Bard Associates Inc, Mesirow Financial Investment Management, Inc., Renaissance Technologies Llc, Geode Capital Management, Llc, HighTower Advisors, LLC, Essex Investment Management Co Llc, and Blair William & Co/il. Charles Davidson is noted as owning the most shares of Nephros, Inc.